JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

Patent filing marks another milestone in becoming a world leader in pain management

LAS VEGAS, June 28, 2023 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery Disease (PAD) and Complex Regional Pain Syndrome (CRPS), has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain.

Dr. Amol Soin, the chief medical officer and inventor mentioned, "This patent filing, should it issue, will bolster our plans to help treat patients suffering from complex regional pain syndrome across the globe, using our novel formulation and dosing strategy that we feel will be advantageous with our drug candidate, Jan123."

JanOne is developing Jan123 (a novel formulation of low dose naltrexone) to treat CRPS, an orphan disease with no current FDA-approved treatments. CRPS leaves patients in debilitating pain and suffering and, as a result, oftentimes patients resort to opioid pain medications. "We believe that Jan123 may offer hope to patients with CRPS and look forward to conducting a large-scale, clinical trial to facilitate FDA approval", noted Dr. Soin.  "It appears this debilitating condition is now getting the attention it deserves from the media with the premier of the Netflix documentary, entitled TAKE CARE OF MAYA." Dr. Soin concluded.

"This international patent application is part of our strategy to help patients around the world who are suffering from this debilitating disease. If this issues, it should bolster our already robust intellectual property portfolio", stated Mr. Tony Isaac the CEO of JanOne.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the statements that Jan101 will treat PAD, that Jan123 will treat CRPS, the timing of the commencement of further clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for Jan123, that upon approval Jan101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope" "should", "would", "may", "potential" and other similar expressions.  Such statements reflect JanOne's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by JanOne, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause JanOne's actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC").

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in JanOne's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

About JanOne Inc.

JanOne is a unique Nasdaq-listed company offering innovative, actionable solutions that it believes can help end the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

Please visit www.janone.com for additional information.

Media Contact
Investor Relations
[email protected]
1-800-400-2247

SOURCE JanOne Inc.